ATAI Life Sciences Announces Joint Venture with DemeRx to Develop Ibogaine For Opioid Use Disorder

January 24, 2020 Articles 9:30 am

A  global biotech platform that envisions an end to mental illnesses, today announced an investment in two separate joint ventures (JV) with DemeRx, a clinical stage pharmaceutical company focused on developing ibogaine and noribogaine for the treatment of opioid use disorder (OUD).

JOIN OUR MAILING LIST

Sign up to receive the latest news on atai.

Email
submit